💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tofacitinib Citrate

CHEMBL2103743 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
504.5 g/mol
LogP
—
Phase
4

A citrate salt form of tofacitinib with the same therapeutic properties. This oral JAK inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis in patients who have not responded adequately to other treatments.

الوزن الجزيئي

504,5000 g/mol

TPSA

221,00 Ų

المجالات العلاجية

Age-Related Macular Degeneration Respiratory Disease Pain Management Rheumatoid Arthritis Migraine Generalized Anxiety Disorder Inflammatory Bowel Disease Psoriasis Systemic Lupus Erythematosus Lymphoma Transplant Medicine Atopic Dermatitis Chronic Pain

آلية العمل

Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12.O=C(O)CC(O)(CC(=O)O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C16H20N6O.C6H8O7/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t11-,13+;/m1./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H28N6O8

                    

                    
                    

                        
HBD / HBA

                        
5 / 12

                    

                    
                    

                        
الروابط القابلة للدوران

                        
8

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
36

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A citrate salt form of tofacitinib with the same therapeutic properties. This oral JAK inhibitor is used to treat moderate to severe rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis in patients who have not responded adequately to other treatments.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Tofacitinib Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2103743.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10174505.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.